The Indian contract research, development and manufacturing services firm Syngene International Ltd. says it has what it takes to rein in the cost element to make therapeutics based on the new star modality, messenger RNA (mRNA), “more dominant” across markets.
Syngene’s chief operating officer, Dr Mahesh Bhalgat, said that while the company’s facilities for biologics are also set up to do mRNA manufacturing, providing a cost advantage by not having...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?